Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 – Innovative Immuno-oncology
Helsinki, Finland, 23 May 2023: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in its Phase I trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor types.
